title: Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
abstract: We designed intermediate dose etoposide + G-CSF 16 microg/kg as a Peripheral Blood Stem Cell (PBSC) mobilization schedule suitable for outpatient administration. Forty-one Lymphoma patients received intermediate dose etoposide (200 mg/m(2) i.v. day +1, +2, +3) +G-CSF 16 microg/kg/day. Results of PBSC mobilization in these patients were compared with those of a group of 37 lymphoma patients mobilized using cyclophosphamide (CTX) at dosage of 4 g/m(2) + G-CSF 10 microg/kg/die. Mean peak of CD34+ cells achieved in P.B. and total CD34+ cells harvested were higher in patients mobilized with intermediate dose etoposide (p = 0.003 and p = 0.004, respectively). After transplantation recovery of polymorphonucleate neutrophils (PMN) > 0.5 x 10(9)/L did not differ significantly between groups: 11.7 days in intermediate dose etoposide group and 11.5 days in CTX group (p = 0.7). Intermediate dose etoposide + G-CSF 16 microg/kg resulted in a maximum length of neutropenia (PMN < 0.5 x 10(9)/L) of 2 days and neutropenic fever was registered during only 3/41 courses (7.3%). Intermediate dose etoposide + G-CSF 16 microg/kg is a highly effective mobilizing therapy, further, it has the advantage of low hematologic toxicity and can be easily administered as outpatient treatment.
authors.affiliation: Divisione Clinicizzata di Ematologia e Unità di Trapianto di Midollo Osseo, Catania, Italy. guwgim@tin.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Milone
authors.forename: Salvatore
authors.initials: S
authors.lastname: Leotta
authors.forename: Katia
authors.initials: K
authors.lastname: Battiato
authors.forename: Pamela
authors.initials: P
authors.lastname: Murgano
authors.forename: Salvatore
authors.initials: S
authors.lastname: Mercurio
authors.forename: Aurora
authors.initials: A
authors.lastname: Strano
authors.forename: Massimo
authors.initials: M
authors.lastname: Poidomani
authors.forename: Stefania
authors.initials: S
authors.lastname: Coppoletta
authors.forename: Elisa
authors.initials: E
authors.lastname: Mauro
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Avola
authors.forename: Valeria
authors.initials: V
authors.lastname: Pinto
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Camuglia
authors.forename: Rosario
authors.initials: R
authors.lastname: Giustolisi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007937:Leukapheresis; D008223:Lymphoma / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000166:cytology*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide